Park Ha Biological Technology (BYAH) investor relations material

Company overview and business model

• Operates as a Cayman Islands holding company with business conducted through PRC subsidiaries and VIEs focused on skincare product development, direct sales, and franchise promotion in China.

• The brand specializes in solutions for problematic skin, offering nearly 70 proprietary products across 10 series, with a strong focus on small molecule peptide technology.

• Franchise network includes 22 franchisees as of October 31, 2025, primarily in Jiangsu Province, with expansion supported by social marketing and community-based events.

• Growth strategies include expanding R&D partnerships, vocational training, social media marketing, supply chain improvements, and strategic investments or acquisitions.

Financial performance and metrics

• As of April 15, 2026, public float was approximately $5.14 million, based on 4,510,446 Class A Ordinary Shares held by non-affiliates at $1.14 per share.

• In August 2025, $1.4 million was transferred from the holding company to a PRC subsidiary as investment.

• No dividends or distributions have been made to shareholders or between subsidiaries as of the prospectus date.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for business expansion, including directly operated stores in China, as indicated in applicable prospectus supplements.

• Intends to retain most available funds and future earnings for operations and expansion, with no anticipated cash dividends in the foreseeable future.